Q-omics provides the consensus-scored GAPDHP73 profile across patient tissues and cancer cell-line models. GAPDHP73 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GAPDHP73 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GAPDHP73 RNA expression shows 8,080 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, KIRC, and ESCA as cancer lineages where GAPDHP73 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP73 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP73 survival associations across molecular data types. GAPDHP73 RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP73 RNA expression–survival associations across cancer types. High GAPDHP73 expression shows unfavorable associations in MESO, LUAD, STAD, ACC and KIRP, but favorable associations in READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GAPDHP73 RNA expression.
This table summarizes GAPDHP73 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP73. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP73 shows higher tumor expression in KIRC, LUAD, KIRP, BRCA, HNSC and LUSC. The KIRC box plot shows higher GAPDHP73 RNA expression in tumor versus normal tissue (log2 FC = +0.232, t-test p < 0.001).
This table shows molecular features associated with GAPDHP73 in patient tissues and cancer cell lines. In patient samples, GAPDHP73 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
